30 related articles for article (PubMed ID: 38566392)
1. Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate.
Fang P; You M; Cao Y; Feng Q; Shi L; Wang J; Sun X; Yu D; Zhou W; Yin L; Mei F; Zhu X; Cheng A; Tan X
J Pharm Biomed Anal; 2024 Jun; 248():116318. PubMed ID: 38908237
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
Fuh FK; Looney C; Li D; Poon KA; Dere RC; Danilenko DM; McBride J; Reed C; Chung S; Zheng B; Mathews WR; Polson A; Prabhu S; Williams M
Br J Pharmacol; 2017 Apr; 174(8):628-640. PubMed ID: 28009435
[TBL] [Abstract][Full Text] [Related]
3. Time-varying brentuximab vedotin pharmacokinetics and weight-based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6-11 years.
Zhang D; Zhang Z; Lee A; Fenton K; Jain S; Garg A; Chia YL
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38866401
[TBL] [Abstract][Full Text] [Related]
4. A β-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E.
Renoux B; Fangous L; Hötten C; Péraudeau E; Eddhif B; Poinot P; Clarhaut J; Papot S
Medchemcomm; 2018 Dec; 9(12):2068-2071. PubMed ID: 30746064
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
Li C; Zhang C; Li Z; Samineni D; Lu D; Wang B; Chen SC; Zhang R; Agarwal P; Fine BM; Girish S
MAbs; 2020; 12(1):1699768. PubMed ID: 31852341
[TBL] [Abstract][Full Text] [Related]
6. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
7. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
8. A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs.
Singh AP; Guo L; Verma A; Wong GG; Shah DK
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30823607
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
[TBL] [Abstract][Full Text] [Related]
10. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates.
Chang HP; Cheung YK; Liu S; Shah DK
Br J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38566392
[TBL] [Abstract][Full Text] [Related]
11. Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates.
Fu Z; Gao C; Wu T; Wang L; Li S; Zhang Y; Shi C
iScience; 2023 Oct; 26(10):107778. PubMed ID: 37727735
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin.
Choules MP; Zuo P; Otsuka Y; Garg A; Tang M; Bonate P
J Pharmacokinet Pharmacodyn; 2023 Aug; ():. PubMed ID: 37632598
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
